US 12,073,932 B2
Determination of adjustments to fluid delivery settings
Benyamin Grosman, Winnetka, CA (US); Di Wu, Palo Alto, CA (US); Louis J. Lintereur, Boise, ID (US); Anirban Roy, Agoura Hills, CA (US); Neha J. Parikh, West Hills, CA (US); Patrick E. Weydt, Moorpark, CA (US); and Ali Dianaty, Porter Ranch, CA (US)
Assigned to MEDTRONIC MINIMED, INC., Northridge, CA (US)
Filed by MEDTRONIC MINIMED, INC., Northridge, CA (US)
Filed on Oct. 25, 2021, as Appl. No. 17/509,670.
Application 17/509,670 is a continuation of application No. 16/386,104, filed on Apr. 16, 2019, granted, now 11,158,413, issued on Oct. 26, 2021.
Application 16/386,104 is a continuation in part of application No. 15/960,495, filed on Apr. 23, 2018, granted, now 11,147,919, issued on Oct. 19, 2021.
Claims priority of provisional application 62/686,040, filed on Jun. 17, 2018.
Prior Publication US 2022/0044785 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. G16H 20/17 (2018.01); A61B 5/00 (2006.01); A61M 5/172 (2006.01); G16H 50/50 (2018.01); A61M 5/142 (2006.01)
CPC G16H 20/17 (2018.01) [A61B 5/4839 (2013.01); A61M 5/1723 (2013.01); G16H 50/50 (2018.01); A61M 2005/14208 (2013.01); A61M 2005/14288 (2013.01); A61M 2005/14296 (2013.01); A61M 2205/52 (2013.01); A61M 2230/201 (2013.01)] 20 Claims
OG exemplary drawing
 
1. A processor-implemented method of automatically adjusting at least one parameter of an insulin delivery controller of an insulin delivery device to regulate delivery of insulin to a user, the processor-implemented method comprising:
obtaining therapy-related data associated with operation of the insulin delivery device for a number of days in the past, the therapy-related data including sensor glucose data for the user and meal data for the user;
determining, from the therapy-related data, an expected value of a fasting blood glucose that corresponds to fasting periods, and an expected value of estimated plasma insulin concentration at the expected value of the fasting blood glucose;
determining at least one adjusted parameter for the insulin delivery controller based on (1) the therapy-related data, and (2) at least one of the expected value of the fasting blood glucose or the expected value of estimated plasma insulin concentration at the expected value of the fasting blood glucose; and
causing the insulin delivery controller to control insulin delivery by the insulin delivery device in accordance with the determined at least one adjusted parameter.